A Study of LY317615 in Patients With Brain Tumors

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

1. The safety of LY317615 and any side effects that might be associated with the drug.

2. Whether LY317615, can help patients with brain tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company

Criteria

Inclusion Criteria:

• You must be at least 18 years old

• You must have been diagnosed with a recurrent brain tumor by MRI or CT scan

• You must be able to swallow the LY317615 tablets

Exclusion Criteria:

• You are a woman who is pregnant or breastfeeding

• In view of your doctor, you have significant heart, liver, kidney, or psychiatric disease